Collectively, these data show that therapeutic blockade of the SMYD3/CDCP1 axis disables tumor-promoting CAF activation, restrains hepatic metastatic outgrowth, and sensitizes CRC to oxaliplatin, supporting this axis as a tractable target to improve chemotherapy response. This evidence concerns the gene SMYD3 and neoplasm.